Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis

Table 1 Characteristics of studies included in the meta-analysis

Year-Author	Location	H. pylori infection initial diagnosis/re-checking	Control group-Day	Fourth-generation quinolone group-Day	Eradication rate (ITT)(control group/fourth- generation quinolone group)	Eradication rate (PP)(control group/fourth- generation quinolone group)	Compliance	Side effects
2017-Mansour Ghanaei, F	Iran	14C-UBT or histology	BPAC-10	BPAG-10	89% (81/91)/77% (70/91)	91% (81/90)/77.8% (70/90)
2015-Masoodi, M	Iran	13C-UBT, RUT pathology test	OBAC-10	OBAG-10	61.6% (37/60)/66.6% (40/60)	67.2% (37/55)/72.7% (40/55)	97.1%/98.3%	37/19
2014-Rakici, H	Turkey	pistology, stool antigen test	LanAL-10	LanAM-10	89.4% (92/103)/87.8% (93/106)	92% (92/100)/91.8% (93/102)	96%/95.1%	-
2013-Murakami, K	Japan	culture method, RUT, UBT	LanAL-7	LanAS-7	43.1% (28/65)/70% (49/70)	43.7% (28/84)/72.1% (49/68)	98.4%/94.1%	11/11
2012-Zeng, Z	China	14C-UBT	EAC-7	EAM-7	78.9% (180/228)/79.4% (181/228)	82.9% (180/217)/84.2% (181/215)	-	-
2009-Lu, NH	China	14C-UBT	EAC-7	EAM-7	90.3% (28/31)/85.7% (24/28)	-	-	-
2008-Kilic, ZM	Turkey	gastroscopy, histology, RUT, 13C-UBT	RBCAC-14 EAC-14	RBCAM-14	76.7% (23/30)/66.7% (20/30)	76.7% (23/30)/66.7% (20/30)	100%/100%	11/13
				EAM-14	63.3% (19/30)/53.3% (16/30)	63.3% (19/30)/53.3% (16/30)	100%/100%	17/21
2007-Bago, P	Croatia	RUT, histology, culture test, 13C-UBT	LanMetC-7 LanAC-7	LanMetM-7	70.4% (50/71)/93.5% (58/62)	75.8% (50/66)/96.7% (58/60)	-
				LanAM-7	78.2% (61/78)/86.4% (57/66)	80.2% (61/76)/90.5% 57/63)
2005-Kist, M	Germany	13C-UBT	EAC-7 ETC-7	EAM-7	72.5% (58/80)/87.5% (70/80)	78% (58/74)/89% (70/79)	-	-
				ETM-7	75% (60/80)/90% (72/80)	79% (60/76)/92% (72/78)
2005-Nista, EC	Italy	Histological examination, 13C-UBT	ETC-7 EAC-7	ETM-7	75% (60/80)/90% (72/80)	78.9% (60/76)/92.3% (72/78)	-	29/11
				EAM-7	72.5% (58/80)/87.5% (70/80)	78.4% (58/74)/88.6% (70/79)		26/10

A: Amoxicillin; B: Bismuth; C: Clarithromycin; E: Esomeprazole G: Gemifloxacin; Lan: Lansoprazole; L: Levofloxacin; M: Moxifloxacin; Met: Metronidazole; O: Omeprazole; P: Pantoprazole; S: Sitafloxacin; RBC: Ranitidine bismuth citrate; -: Not reported.

Table 2 Risk assessment of included studies

Year-Author	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
2017-Mansour Ghanaei, F	L	H	H	L	L	L	L
2015-Masoodi, M	L	L	L	H	L	L	L
2014-Rakici, H	L	H	H	H	L	U	L
2013-Murakami, K	L	H	L	H	L	L	L
2012-Zeng, Z	U	U	U	U	L	U	U
2009-Lu, NH	U	U	U	U	L	U	U
2008-Kilic, ZM	L	H	H	H	L	L	U
2007-Bago, P	L	L	L	H	L	L	L
2005-Kist, M	H	H	H	H	L	H	L
2005- Nista, EC	L	H	H	H	L	L	L

L: Low risk of bias; H: High risk of bias; U: Unclear risk of bias.